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In this study two cDNA expressing libraries generated from thyroid papillar carcinomas were screened 
using SEREX approach. Thirty positive cDNA clones representing seventeen different genes were identified 
from both libraries. It is important to note, that three of them were isolated previously by other laboratories 
in SEREX screens of various types of human cancer. These include transcription factor NZF, a-catenin 
and ВАС RPU—a protein with unknown function. Moreover, we identified a whole panel of novel 
potential tumor-associated antigens, which would be further investigated. We are particularly interested in 
more detailed analysis of cathepsin H and transducer of ErbB2 (TOB2), which are differentially expressed 
in various types of human cancer. We will analyse the frequency of autoantibodies against identified 
antigens in sera of patients with various malignancies and healthy donors by heterologous screening. It is 
expected that among the clones isolated in this study, there might be novel cancer-associated markers. 
Introduction. Thyroid cancer, although the most fre­
quent malignancy of the endocrine system, is in 
general a rare disease. It accounts for about 1 % of 
all human cancers, with a higher prevalence in women 
(5—9 of 100000) as compared with men (2—4 of 
100000) [1]. Normally, thyroid cancer is a disease 
with good prognosis, but about 30 % of tumors 
dedifferentiate and may finally develop into highly 
malignant anaplastic thyroid carcinomas with the 
mean survival time of less than 8 months. The thyroid 
gland is highly sensitive to radiation-induced on­
cogenesis. This is verified by numerous reports from 
survivors after Hiroshima and Nagasaki, the Nevada, 
Novaya Zemlya and Marshal Island atomic bomb 
tests [2]. Investigations provided after Chernobyl 
nuclear plant accident have shown the increase of 
thyroid cancer two fold in adults and three fold in 
children. 
The success of cancer therapy depends on the 
stage of the disease detection. Today, the specific 
markers for early detection of thyroid cancer are 
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unknown and the search for them is a problem of 
outstanding value. 
At present, several methods for the search of 
tumor-associated antigens exist, such as DNA Micro-
arrays, SAGE, CNAPS, SEREX (Serological analysis 
of recombinant cDNA expressing libraries) with their 
advantages and deficiencies [3]. SEREX method is 
based on the study of cancer patient's immune 
response. Samples of cancer tissue are used for the 
creation of expressing cDNA libraries further scree­
ned by autologous sera. This method is suitable for 
the identification of the proteins (or their immuno­
genic epitopes) that cause immune responses in can­
cer patients. 
SEREX method has been successfully applied for 
the detection of tumor-associated antigens from vari­
ous types of human cancer, including breast, colo­
rectal, renal etc. [4—6]. 
These studies led to the identification of several 
novel antigens, which are currently used as markers 
of malignant transformation and for the production of 
anti-cancer vaccines [7 ]. We have previously reported 
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the identification of 15 immunoreactive clones isolated 
by SEREX screening of thyroid cancer cDNA exp­
ressing libraries [8 ]. We have extended the search for 
novel antigens by generating and screening of two 
novel libraries from thyroid papillar cancer. Here, we 
report the identification of further 30 immunoreactive 
clones, representing 17 genes. It is important to note 
that three from identified genes have been previously 
found by SEREX approach from other types of human 
cancer. Heterologous screens of isolated clones with a 
panel of sera from healthy donors and patients with 
various types of cancer is currently in progress. 
Materials and Methods. The samples of human 
thyroid papillar carcinomas and autologous sera were 
kindly provided by Dr. V. Usenko and Dr. V. 
Lysogubov (BIONTEC, Ukraine). 
Purification of total and messenger RNA. Total 
RNA was purified from freshly frozen in liquid 
nitrogen tumor samples by the modified guanidine-
isothiocyanate method [9 J. mRNA was isolated by 
affinity chromatography using oligo(dT) Dynabeds 
matrix («Dynal», UK). The quality and quantity of 
the preparations obtained were estimated by spectro-
photometrical methods and by the electrophoresis in 
1 % formaldehyde-agarose gels. The mRNA prepa­
rations were stored under ethanol at -80 °С until 
further use. 
Generation of cDNA expressing libraries. Five 
micrograms of purified mRNA preparations were 
applied for cDNA synthesis with the use of cDNA 
synthesizing kit («Stratagene», USA). The oligonuc­
leotide primer containing Xhol site and an oligo(dT) 
tail was used for the initiation of reverse transcription. 
The effectiveness of the synthesis was estimated with 
the use of the test RNA preparation from Stratagene 
kit followed by electrophoresis in 1 % agarose gels. 
cDNA fragments accounting 0.5—3 kb were 
extracted from the gels using DNA extraction kit 
(«Qiagen», USA). The fragments obtained were clo­
ned into bacteriophage Я DNA (UniZap vector) by 
Xhol and EcoRI restriction sites. The phagemide 
obtained was packed into phage particles with the use 
of Gigapack Gold III kit («Stratagene», USA). For the 
estimation of primary libraries titers Escherichia coli 
XL-1 Blue MRF' cells were infected by recombinant 
phages in appropriate dilutions. The percentage of 
non-recombinant phages was detected by blue/white 
plaque selection in the presence of IPTG and X-Gal 
(«Sigma», USA). 
Affinity purification of the sera. Sera samples 
from patients with thyroid cancer were diluted 1:1 
with glycerol and stored at -20 °С until further use. 
For the affinity purification, prepared sera samples 
were diluted 1:10 by TBS (10 mM Tris-HCl, pH 8.0, 
150 mM NaCl) and incubated with affinity matrixes 
containing covalently crosslinked E. coli and Я phage 
proteins (Y1090 and BNN97 matrixes respectively). 
This technique allowed the elimination of serum 
immunoglobulins directed against bacterial and phage 
proteins. The depleted sera were further diluted by 
TBS 1:100 and stored at 4 °С with the addition of 
0.02 % NaN 3. 
Immunoscreening of cDNA expression libraries. 
For the primary screening 600 /лі of E. coli XL-1 Blue 
MRF' cells were infected with 6* 10 s phage particles 
and plated onto 150 mm Petri dishes. The expression 
of recombinant proteins was induced by the addition 
of 1 mM IPTG for 5—7 hours. The transfer of the 
proteins to the nitrocellulose membrane Hybond-C 
was carried out overnight by standard method. 
The identification of IgG expressing clones was 
performed by immunoblotting of filters with anti-
human horse radish peroxidase conjugate (dilution 
1:2000, «Sigma», USA). Detection of primary posi­
tives was carried out by probing filters with the 
autologous sera and anti-human alkaline phosphatase 
conjugate staining. Positive clones were extracted 
from the agar and stored in 0.5 ml of SM buffer with 
the addition of 20 ці of chloroform. 
The secondary screening of isolated clones was 
performed on 90 mm Petri dishes by the same 
method. Plasmid DNA from positive clones was 
obtained by in vivo recombination in E. coli strain 
XL-1 Blue MRF'. 
Restriction analysis and sequencing of isolated 
clones. The size of cDNA insertions was detected by 
restriction analysis with EcoRI and Xhol endonuc-
leases followed by 1 % agarose gel electrophoresis. 
Sequencing of the inserts was performed by a stan­
dard protocol using the automatic sequencer ABI 373 
(Applied Biosystem). The identification of positive 
clones and their analysis was performed with a help 
of EMBO, GenBank, dBest and SEREX databases. 
Results and Discussion. Taking into conside­
ration the increase of thyroid cancer frequency and 
the absence of specific markers for early diagnostic 
purposes we have extended our search for thyroid 
cancer associated markers. In this study, we have 
used SEREX methodology aimed on the identification 
of tumor-associated proteins which induce immune 
response in cancer patients. We have successfully 
applied SEREX technique in previous studies, which 
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led us to the identification of 25 immunoreactive 
clones from thyroid cancer and melanoma [8, 10]. 
In order to extend the search for novel antigens, 
we have created two additional cDNA expressing 
libraries from thyroid papillar carcinomas with the 
titer of 1.05 and 1.4 • 106 respectively. The percentage 
of non-recombinant phages was less than 1 % for 
both libraries. These tests indicated that both li­
braries are suitable for immunoscreening by SEREX 
methodology. 
The primary immunoscreening with autologous 
sera allowed us to isolate 170 primary positives 
clones, which showed various degree of immuno-
reactivity. It is important to note that we picked up 
clones which exhibited even a very weak immunoreac-
tivity (a borderline with non-specific signal). There­
fore, a large number of primary clones were not 
confirmed by secondary screenings, leaving only 30 
clones as true-positives. cDNA plasmids, correspon­
ding to positive clones, were rescued by in vitro 
recombination approach. The size of inserts in isola­
ted plasmids were determined by restriction analysis 
(data not shown). The identification of isolated clones 
was performed by sequence analysis followed by 
searching of various DNA and protein databases. The 
search revealed that 30 clones encode 17 genes (Table 
1). Furthermore, 12 of them encode known proteins, 
while 5 represent so far genes with unknown func­
tions. The sequence of isolated clones and other 
relevant information were submitted to the SEREX 
database http://www.licr.org/SEREX.html. 
The analysis of SEREX database revealed that 
three of these genes were identified earlier by other 
SEREX laboratories in screens of different types of 
human cancer (Table 2). These include a potential 
transcription factor NZF, a-catenin and a protein with 
unknown function ВАС RP11. Noteworthy, NZF 
protein was isolated from libraries generated from 
glioma, renal cell carcinoma, ovarian and colon can­
cer, teratoma and normal testis. On the other hand, 
a-catenin was cloned from melanoma, renal, breast, 
colorectal cancer, small cell carcinoma and testis. 
Further analysis of other antigens identified in pre­
sent study showed their relevance to malignant trans­
formation. 
For example, a- and /?-catenins are involved in 
cadherin-mediated cell-cell adhesion. Disregulation of 
cellular functions of both a- and /ї-catenins is asso­
ciated with invasive potential of malignant cells [11— 
13]. The overexpression of ErbB-2 antigen is ob­
served in 30 % of breast cancer and is associated with 
poor prognosis. Moreover, ErbB2 has been also found 
overexpressed in thyroid and other types of human 
cancer [14, 15]. In this study we have isolated the 
transducer of ErbB2 (clone Thy28). So far, very little 
is known about the function of the transducer of 
ErbB2. However, there is no doubt that the function 
of this gene in normal and transformed cells needs 
further investigation. 
Phosphotyrosine independent ligand p62 for the 
Lck SH2 domain (Thy36) is a major component of 
intracytoplasmic hyaline bodies in hepatocellular car­
cinoma cells, while in non-neoplastic liver cells it was 
not observed [16]. p62 protein binds ubiquitin and 
may act as an adapter linking ubiquitinated proteins 
to multienzyme proteosomal complexes to other pro­
teins. These features suggest a role for p62 in signal 
transduction and possibly also in carcinogenesis. 
Elevated expression of proteases is observed in a 
variety of tumors. Clone Thy40 encodes a protease — 
cathepsin H, whose expression is increased in high-
grade prostatic intraepithelial neoplasia and carci­
noma of the prostate [17 ]. Two forms of cathepsin are 
known: a full length and a truncated version. Both of 
them are enzymatically active, but truncated form has 
a reduced lysosomal association when compared with 
a full-length cathepsin H. It was suggested that 
increased expression of cathepsin H may affect cellu­
lar functions especially those which are associated 
with tumor progression and metastasis. Short-chain 
collagen type VIII (Thy43) was observed throughout 
the development of hemangioma in the study of Tan 
et al. [18]. It was also detected within mast cells 
during early proliferative phase. In several SEREX 
studies different ribosomal proteins have been iden­
tified as tumor-associated antigens [19, 20]. We have 
identified ribosomal protein S24 (Thy32 and 35) 
which has not been previously detected in serological 
screenings by SEREX or other approaches. Several 
clones corresponding to non-sarcomeric myosin light 
chain (Thy37, 38 and 42) have been also isolated in 
our screen. In our previous article [8] we have 
reported SEREX-based detection of CDC-42 binding 
protein kinase. Phosphorylation of myosin light chain 
by CDC-42 binding protein kinase leads to the 
activation of actin-myosin contractility [21 ]. Dis­
regulation in actin-myosin contractility, induced by 
aberrant signaling may play a role in malignant 
invasiveness and metastatic growth [22 ]. 
The clone KY-Thy29 encodes for the solid tumor 
associated protein. Two STAG1/PMEPA1 mRNA 
transcripts of approximately 2.7 and 5 kb, with 
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Table 1 
Immunoreactive clones isolated by SEREX screening of thyroid cancer libraries 
Group number Clone (SEREX ID) Homology/Identiry 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Cathepsin H (CTSH) 
Proteine phosphatase 1, regulatory (inhibitor) subunit 15A 
Collagen, type VIII, alpha 2 
Clone XXbac-44E15 on chromosome 6 
identical coding regions but variant 3' untranslated 
regions, were predominantly expressed in normal 
prostate tissue and at lower levels in the ovary. The 
expression of this gene was upregulated in 87 % of 
RCC samples and also was upregulated in stomach 
and rectal adenocarcinomas. 
In contrast, STAG1/PMEPA1 expression was 
barely detectable in leukemia and lymphoma samples. 
Analysis of expressed sequence tag databases showed 
that STAG1/PMEPA1 also was expressed in pancrea­
tic, endometrial, and prostatic adenocarcinomas. The 
STAG1/PMEPA1 cDNA encodes a 287-amino-acid 
protein containing a putative transmembrane domain 
and motifs that suggest that it may bind src homology 
3- and tryptophan domain-containing proteins. This 
protein shows 67 % identity to the protein encoded 
by the chromosome 18 open reading frame 1 gene. 
Translation of STAG1/PMEPA1 mRNA in vitro sho­
wed two products of 36 and 39 kDa, respectively, 
suggesting that translation may initiate at more than 
one site. The upregulation of this gene in several solid 
tumors indicated that it may play an important role 
in tumorigenesis [23]. The link between identified 
antigens and various aspects of malignant trans­
formation, based on the literature search, is summa­
rized in Table 3. Our further investigations will be 
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Table 2 
The summary of serological properties and expression pattern of 3 genes, which were identified earlier in different SEREX screenings 
Our clone (SEREX ID) Homology/Identi ty Group mRNA sourse/serum Characteristics 
KY-Thy 17 (2313) C2H2 zinc finger University of Mainz 
protein (NZF) 
KY-Thy22 (2418) 
Table 3 
A possible link between SEREX-derived antigens from human thyroid carcinoma and malignant transformation 
Group number Clones Homology 
Possible role in cancer 
development and progression 
Catenin beta-like 1 
Alpha-catenin 
Transducer of ErbB2 
Sequestesoma 1 
Non-sarcomeric myosin, light 
polypeptide 
Cathepsin H (CTSH) 
Proteine phosphatase 1, regulatory 
(inhibitor) subunit 15A 
Collagen, type VIII, alpha 2 
The levels of catenin expression in tumor tissue differs 
from the normal ones 
a-Catenin meets the criteria of an invasion suppressor 
gene 
The expression in thyroid carcinomas correlates with the 
degree of aggressiveness and differentiation 
Major component of intracytoplasmic hyaline bodies in 
hepatocellular carcinoma 
Involved in invasion and metastasis of pancreatic cancer 
Increased expression in high-grade prostatic intra­
epithelial neoplasia and carcinoma of the prostate 
Involved in down-regulation of signalling pathways, 
inducing growth and proliferation 
Short-chain collagen is localized extracellulary 
throughout the development of hemangioma 
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focused on the elucidation of the role of identified 
antigens in cancerogenesis. Heterologous screenings 
with a panel of sera from healthy donors and patients 
with various types of cancer would allow us to select 
those which have the properties of tumor specific 
markers or the potential for the development of 
anti-cancer vaccines. 
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M. В. Роднін, I. О. Тихонкова, P. Г. Кіямова, О. M. Гарифулін, 
І. Т. Гут, В. В. Філоненко 
Ідентифікація пухлиноасоційованих антигенів папілярної 
карциноми щитовидної залози людини 
Резюме 
З двох зразків тканини папіломи щитовидної залози людини 
отримано дві кДНК експресуючі бібліотеки. Імуноскрину-
ванням бібліотек методом SEREX ідентифіковано ЗО пози­
тивних клонів, які відповідали 17 різним генам. Потрібно 
відмітити, що три гени — транскрипційний фактор NZF, 
а-катенін і білок ВАС RP11 з поки невідомою функцією — 
раніше виявлено в інших лабораторіях методом SEREX, де 
скрикували бібліотеки з різних типів пухлин людини. Серед 
решти ідентифікованих генів найцікавішими є катепсин Н 
(cathepsin Н) и ТОВ2 (transducer of ErbB2), підвищену екс­
пресію яких було знайдено в багатьох злоякісних пухлинах 
людини. Подальші дослідження буде направлено на виявлення 
частоти зустрічальності антитіл проти даних антигенів у 
сироватках крові хворих на рак різної етіології та здорових 
донорів. Серед визначених у нашій лабораторії нових SEREX 
позитивних клонів є потенційні маркери злоякісних новоутво­
рень щитовидної залози людини. 
Н. В. Роднин, И. А. Тихонкова, Р. Г. Киямова, 
О. М. Гарифулин, И. Т. Тут, В. В. Филоненко 
Идентификация опухолеассоциированных антигенов 
папиллярной карциномы щитовидной железы человека 
Резюме 
кДНК экспрессирующие библиотеки получены из двух образцов 
ткани злокачественной папилломы щитовидной железы чело­
века. Иммуноскрининг библиотек методом SEREX дал воз­
можность идентифицировать 30 положительных клонов, пред­
ставляющих собой продукты 17 различных генов. Следует 
отметить, что три гена — транскрипционный фактор NZF, 
а-катенин и белок с неизвестной функцией ВАС RP11 — 
выявлены ранее в других лабораториях SEREX скринингом 
библиотек из различных типов опухолей человека. Среди ос­
тальных идентифицированных генов наибольший интерес 
представляют катепсин Н (cathepsin Н) и ТОВ2 (transducer of 
ErbB2), повышенная экспресия которых выявлена во многих 
злокачественных опухолях человека. Дальнейшие исследования 
будут направлены на установление частоты встречаемости 
антител против данных антигенов в сыворотках крови боль­
ных раком различной этиологии и здоровых доноров. Среди 
выявленных нами новых SEREX положительных клонов могут 
быть потенциальные маркеры злокачественных новообразова­
ний щитовидной железы человека. 
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